We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.41%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$20.1B
AUM Growth
+$345M
(+1.7%)
Cap. Flow
-$629M
Cap. Flow
% of AUM
-3.12%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
726
New
45
Increased
386
Reduced
252
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freeport-McMoran
FCX
|
+$153M |
| 2 |
GG
Goldcorp Inc
GG
|
+$135M |
| 3 |
B
Barrick Mining
B
|
+$83.5M |
| 4 |
FMC
FMC
|
+$71.4M |
| 5 |
Nabors Industries
NBR
|
+$67.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Occidental Petroleum
OXY
|
+$180M |
| 2 |
MON
Monsanto Co
MON
|
+$99.5M |
| 3 |
Archer Daniels Midland
ADM
|
+$98.2M |
| 4 |
Deere & Co
DE
|
+$86.9M |
| 5 |
POT
Potash Corp Of Saskatchewan
POT
|
+$83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 44.67% |
| 2 | Energy | 26.42% |
| 3 | Healthcare | 5.22% |
| 4 | Industrials | 4.4% |
| 5 | Consumer Staples | 3.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Merck
MRK
$324B
| $16.4M | 0.08% |
303,365
+17,721
| +6% | +$918K |
|
152
Sanofi
SNY
$104B
| $16.2M | 0.08% |
310,591
+58,078
| +23% | +$2.94M |
|
153
Micron Technology
MU
$1.04T
| $15.8M | 0.08% |
666,335
+12,953
| +2% | +$308K |
|
154
AbbVie
ABBV
$458B
| $15.7M | 0.08% |
305,479
+65,142
| +27% | +$3.29M |
|
|
NVO
155
Novo Nordisk
NVO
$216B
| $15.6M | 0.08% |
685,568
+43,218
| +7% | +$921K |
|
156
Applied Materials
AMAT
$426B
| $15.6M | 0.08% |
763,539
-16,264
| -2% | -$299K |
|
|
PCYC
157
DELISTED
PHARMACYCLICS INC
PCYC
| $15.4M | 0.08% |
153,765
+58,629
| +62% | +$7.62M |
|
158
GSK
GSK
$103B
| $15.3M | 0.08% |
229,537
+32,632
| +17% | +$2.21M |
|
|
BRCM
159
DELISTED
BROADCOM CORP CL-A
BRCM
| $15.3M | 0.08% |
486,658
+103,137
| +27% | +$3.11M |
|
160
Analog Devices
ADI
$181B
| $15.3M | 0.08% |
287,965
+24,417
| +9% | +$1.23M |
|
161
Teva Pharmaceuticals
TEVA
$35.9B
| $15.2M | 0.08% |
287,973
+2,515
| +0.9% | +$116K |
|
|
GPL
162
DELISTED
Great Panther Mining Limited
GPL
| $15.2M | 0.08% |
1,500,330
+497,643
| +50% | +$5.05M |
|
|
CVD
163
DELISTED
COVANCE INC.
CVD
| $14.6M | 0.07% |
140,697
+53,098
| +61% | +$5.26M |
|
|
MDVN
164
DELISTED
MEDIVATION, INC.
MDVN
| $14.3M | 0.07% |
443,440
+37,660
| +9% | +$1.39M |
|
|
CBST
165
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $14.2M | 0.07% |
194,702
-4,439
| -2% | -$331K |
|
166
Eli Lilly
LLY
$1.07T
| $14.1M | 0.07% |
239,822
-506,485
| -68% | -$28.3M |
|
167
Vale
VALE
$62.9B
| $14.1M | 0.07% |
1,017,821
-285,409
| -22% | -$3.9M |
|
|
XLNX
168
DELISTED
Xilinx Inc
XLNX
| $13.9M | 0.07% |
255,586
+28,308
| +12% | +$1.41M |
|
169
AstraZeneca
AZN
$263B
| $13.8M | 0.07% |
212,951
+10,594
| +5% | +$684K |
|
170
Wolfspeed
WOLF
$1.2B
| $13.8M | 0.07% |
243,971
+4,057
| +2% | +$247K |
|
171
Abbott
ABT
$180B
| $13.8M | 0.07% |
357,979
+46,534
| +15% | +$1.79M |
|
172
Rio Tinto
RIO
$148B
| $13.7M | 0.07% |
245,666
-99,876
| -29% | -$5.44M |
|
|
AGN
173
DELISTED
Allergan Inc
AGN
| $13.7M | 0.07% |
110,357
+3,932
| +4% | +$479K |
|
174
Andersons Inc
ANDE
$2.65B
| $13.6M | 0.07% |
229,937
-174,948
| -43% | -$9.8M |
|
|
DRD
175
DRDGold
DRD
$1.82B
| $13.4M | 0.07% |
3,586,840
+1,188,011
| +50% | +$4.7M |
|
Similar funds
DAM
VanEck Associates's Q1 2014 Portfolio in Review
As of Q1 2014, VanEck Associates held 726 positions worth $20.1B, up 1.7% from $19.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
VanEck Associates withdrew a net $629M in Q1 2014, closing 32 positions and reducing 252 holdings. Its most notable exit was Halcon Resources Corporation, an estimated $33.5M position sold in full.
By sector, the portfolio is most concentrated in Materials at 45% of assets, up from 43% a quarter earlier, followed by Energy and Healthcare.
Against the trend, VanEck Associates opened a new position in FMC worth $72.9M.
- VanEck Associates's largest Q1 2014 buy was FMC: 1,097,354 shares worth $72.9M.
- VanEck Associates added most to Freeport-McMoran in Q1 2014, an estimated $153M increase.
- VanEck Associates's biggest Q1 2014 reduction was Occidental Petroleum, cutting an estimated $180M.
- VanEck Associates fully exited Halcon Resources Corporation in Q1 2014, selling an estimated $33.5M.
- VanEck Associates's ten largest holdings make up 30% of its $20.1B portfolio in Q1 2014.
- VanEck Associates opened 45 new positions and closed 32 in Q1 2014.
- VanEck Associates's portfolio value rose 1.7% quarter-over-quarter to $20.1B.
Based on VanEck Associates's 13F filing for Q1 2014, filed 8 May 2014.